Andrew Minchinton

Research

Hypoxia Tumour Microenvironment Prodrugs Radiotherapy Chemotherapy Dna-Pk Radiation Biology Clinical Drug Development

Latest papers

Dosimetric comparability validation of small animal photon and neutron irradiations.
Journal of radiological protection : official journal of the Society for Radiological Protection · 2026
Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.
Journal of translational medicine · 2024
Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.
International journal of molecular sciences · 2021

All 9 publications

Latest funding

Development of clinical candidate hypoxia-activated DNA-PK inhibitors
CIHR · 2023 · Nominated PI
$979,200
Metabolic manipulation of hypoxia for improved radiotherapy response
CIHR · 2021 · Nominated PI
$677,024
FLASH radiotherapy - mechanisms and translational studies
CIHR · 2021 · Nominated PI
$918,000

All 10 grants and awards

9 publications.

01

Dosimetric comparability validation of small animal photon and neutron irradiations.

Tattenberg S, Hands A, Bélanger-Champagne C, Johnstone C, Segars WP, Minchinton A, Vazquez M, Hoehr C

Journal of radiological protection : official journal of the Society for Radiological Protection2026

DOI: 10.1088/1361-6498/ae33cd PMID: 41494205

02

Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.

Kalra J, Baker J, Sun X, Kyle A, Minchinton A, Bally MB

Journal of translational medicine2024

DOI: 10.1186/s12967-024-05428-9 PMID: 38961395

03

Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.

Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M

International journal of molecular sciences2021

DOI: 10.3390/ijms22126336 PMID: 34199298

04

Dosimetry with a clinical linac adapted to FLASH electron beams.

Szpala S, Huang V, Zhao Y, Kyle A, Minchinton A, Karan T, Kohli K

Journal of applied clinical medical physics2021

DOI: 10.1002/acm2.13270 PMID: 34028969

05

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.

Oronsky B, Scicinski J, Cabrales P, Minchinton A

Clinical epigenetics2016Senior author

DOI: 10.1186/s13148-016-0220-7 PMID: 27175220

06

A novel population of local pericyte precursor cells in tumor stroma that require Notch signaling for differentiation.

Patenaude A, Woerher S, Umlandt P, Wong F, Ibrahim R, Kyle A, Unger S, Fuller M, Parker J, Minchinton A, Eaves CJ, Karsan A

Microvascular research2015

DOI: 10.1016/j.mvr.2015.05.004 PMID: 26092680

07

Notch-dependent regulation of the ischemic vasodilatory response--brief report.

Chang AC, Patenaude A, Lu K, Fuller M, Ly M, Kyle A, Golbidi S, Wang Y, Walley K, Minchinton A, Laher I, Karsan A

Arteriosclerosis, thrombosis, and vascular biology2013

DOI: 10.1161/atvbaha.112.300840 PMID: 23288167

08

Notch initiates the endothelial-to-mesenchymal transition in the atrioventricular canal through autocrine activation of soluble guanylyl cyclase.

Chang AC, Fu Y, Garside VC, Niessen K, Chang L, Fuller M, Setiadi A, Smrz J, Kyle A, Minchinton A, Marra M, Hoodless PA, Karsan A

Developmental cell2011

DOI: 10.1016/j.devcel.2011.06.022 PMID: 21839921

09

Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

Lou Y, McDonald PC, Oloumi A, Chia S, Ostlund C, Ahmadi A, Kyle A, Auf dem Keller U, Leung S, Huntsman D, Clarke B, Sutherland BW, Waterhouse D, Bally M, Roskelley C, Overall CM, Minchinton A, Pacchiano F, Carta F, Scozzafava A, Touisni N, Winum JY, Supuran CT, Dedhar S

Cancer research2011

DOI: 10.1158/0008-5472.can-10-4261 PMID: 21415165

Development of clinical candidate hypoxia-activated DNA-PK inhibitors

Nominated PICIHR2023Project Grant

Principal investigators: Minchinton, Andrew I

Keywords: Chemotherapy; Clinical Drug Development; Dna Damage Repair Inhibitors; Dna-Pk; Hypoxia; Prodrug; Prodrugs; Radiotherapy; Screening Cascade; Tumour Microenvironment

$979,200

Metabolic manipulation of hypoxia for improved radiotherapy response

Nominated PICIHR2021Project Grant

Principal investigators: Minchinton, Andrew I

Keywords: Drug Screening; Glycolytic Blockade; Hypoxia; Metabolic Reprogramming; Mitochondria Inhibitors; Prodrugs; Radiotherapy; Re-Oxygenation; Respiratory Chain Inhibitors; Tumour Microenvironment

$677,024

FLASH radiotherapy - mechanisms and translational studies

Nominated PICIHR2021Project Grant

Principal investigators: Minchinton, Andrew I

Keywords: Drug Distribution; Flash Radiation; Hypoxia; Normal Tissue Toxicity; Oxygen Consumption; Radiation Resistance; Therapeutic Index; Tumour Microenvironment; Tumour Oxygenation; Ultra High Dose Radiotherapy

$918,000

Hypoxia-activated DNA repair inhibitors to improve cancer therapy

Nominated PICIHR2019Project Grant

Principal investigators: Minchinton, Andrew I

Keywords: Anti Cancer Drug Development; Chemotherapy; Dna Damage Repair; Dna-Pk; Drug Development; Hypoxia; Prodrugs; Radiation Biology; Radiotherapy; Tumour Microenvironment

$573,750

Hypoxia-selective inhibitors of DNA repair

Principal investigatorNSERC2018Collaborative Health Research Projects

Principal investigators: Minchinton, Andrew

$259,381

Hypoxia-selective inhibitors of DNA repair

Nominated PICIHR2017Collaborative Health Research Projects (NSERC partnered)

Principal investigators: Minchinton, Andrew I; Bacha, Jeffrey; Perrin, David M

Keywords: Dna Repair; Drug Discovery; Medicinal Chemistry; Prodrugs; Radiation Biology; Radiosenstiziation; Radiotherapy; Targeting Hypoxia; Tumour Hypoxia; Tumour Microenvironment

$259,381

Metabolic manipulation of hypoxia and radiotherapy response

Nominated PICIHR2013Operating Grant

Principal investigators: Minchinton, Andrew I

Keywords: Hypoxia; Metabolism; Radiation

$727,090

Intravesicular nanoparticulate drug delivery systems for application in bladder cancer

Principal investigatorCIHR2011Operating Grant

Principal investigators: Burt, Helen M; Bally, Marcel B; Brooks, Donald E; Gleave, Martin E; Minchinton, Andrew I

Keywords: Anticancer Drugs; Bladder Cancer; Blood And Tissue Distribution; Drug Delivery Systems; Hyperbranched Polymers; Mucoadhesion; Nanoparticles

$291,892

Microenvironmental strategies for the optimal utilization of anti-angiogenic drugs combinations

Nominated PICIHR2011Operating Grant

Principal investigators: Minchinton, Andrew I

Keywords: Angiogenesis; Chemotherapy; Hypoxia; Radiation Therapy; Tumour Microenvironment

$662,588

Hypoxia-selective radiation sensitizers

Nominated PICIHR2008Operating Grant

Principal investigators: Minchinton, Andrew I

Keywords: Anticancer Drug; Cancer; Dna Repair; Hypoxia; Radiotherapy

$560,232

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Genome Sciences Centre
Experimental Therapeutics
Cellular and Physiological Sciences
Molecular Oncology
Pediatrics
Medicine
Biochemistry and Molecular Biology
Other

Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Aly Karsan

Genome Sciences Centre

3 shared papers, latest 2015

Marcel Bally

Experimental Therapeutics

2 shared papers, latest 2021

Marco Marra

Genome Sciences Centre

1 shared papers, latest 2011

Keith Walley

Medicine

1 shared papers, latest 2013

David Huntsman

Molecular Oncology

1 shared papers, latest 2011

Calvin Roskelley

Cellular and Physiological Sciences

1 shared papers, latest 2011

Shoukat Dedhar

Biochemistry and Molecular Biology

1 shared papers, latest 2011

Ismail Laher

Pediatrics

1 shared papers, latest 2013

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Hypoxia Dear Professor Minchinton, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Dosimetric comparability validation of small animal photon and neutron irradiations." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Development of clinical candidate hypoxia-activated DNA-PK inhibitors" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]